The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Department of Pharmacology, Shijiazhuang, China.
Br J Pharmacol. 2011 Nov;164(6):1722-37. doi: 10.1111/j.1476-5381.2011.01483.x.
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used for the treatment of pain and inflammation. Emerging and accumulating evidence suggests that celecoxib can affect cellular targets other than COX, such as ion channels. In this study, we characterized the effects of celecoxib on K(v)7 K(+) channels and compared its effects with the well-established K(v)7 channel opener retigabine.
A perforated whole-cell patch technique was used to record K(v)7currents expressed in HEK 293 cells and M-type currents from rat superior cervical ganglion neurons.
Celecoxib enhanced K(v)7.2-7.4, K(v)7.2/7.3 and K(v)7.3/7.5 currents but inhibited K(v)7.1 and K(v)7.1/KCNE1 currents and these effects were concentration dependent. The IC(50) value for inhibition of K(v)7.1 channels was approximately 4 µM and the EC(50) values for activation of K(v)7.2-7.4, K(v)7.2/K(v)7.3 and K(v)7.3/K(v)7.5 channels were approximately 2-5 µM. The effects of celecoxib were manifested by increasing current amplitudes, shifting the voltage-dependent activation curve in a more negative direction and slowing the deactivation of K(v)7 currents. 2,5-Dimethyl-celecoxib, a celecoxib analogue devoid of COX inhibition activity, has similar but greater effects on K(v)7currents. K(v)7.2(A235T) and K(v) 7.2(W236L) mutant channels, which have greatly attenuated responses to retigabine, showed a reversed response to celecoxib, from activation to inhibition.
These results suggest that K(v)7 channels are targets of celecoxib action and provide new mechanistic evidence for understanding the effects of celecoxib. They also provide a new approach to developing K(v)7 modulators and for studying the structure-function relationship of K(v)7 channels.
塞来昔布是一种选择性环氧化酶-2(COX-2)抑制剂,用于治疗疼痛和炎症。新出现的和积累的证据表明,塞来昔布可以影响除 COX 以外的细胞靶标,如离子通道。在这项研究中,我们描述了塞来昔布对 K(v)7 K(+)通道的影响,并将其与成熟的 K(v)7 通道开放剂瑞替加滨的作用进行了比较。
使用穿孔全细胞膜片钳技术记录在 HEK 293 细胞中表达的 K(v)7 电流和大鼠颈上交感神经节神经元中的 M 型电流。
塞来昔布增强了 K(v)7.2-7.4、K(v)7.2/7.3 和 K(v)7.3/7.5 电流,但抑制了 K(v)7.1 和 K(v)7.1/KCNE1 电流,这些作用具有浓度依赖性。抑制 K(v)7.1 通道的 IC(50)值约为 4 μM,激活 K(v)7.2-7.4、K(v)7.2/K(v)7.3 和 K(v)7.3/K(v)7.5 通道的 EC(50)值约为 2-5 μM。塞来昔布的作用表现为增加电流幅度,将电压依赖性激活曲线向更负的方向移动,并减缓 K(v)7 电流的失活。2,5-二甲基塞来昔布,一种缺乏 COX 抑制活性的塞来昔布类似物,对 K(v)7 电流具有类似但更大的作用。K(v)7.2(A235T)和 K(v)7.2(W236L)突变通道对瑞替加滨的反应大大减弱,对塞来昔布的反应则相反,从激活变为抑制。
这些结果表明 K(v)7 通道是塞来昔布作用的靶点,并为理解塞来昔布的作用提供了新的机制证据。它们还为开发 K(v)7 调节剂和研究 K(v)7 通道的结构-功能关系提供了一种新的方法。